Contract Medical and Commercial Organization, Amplity has released a revolutionary AI-driven next best action solution that provides pharmaceutical and biopharmaceutical companies with an entirely new order of field insights that can be acted upon within the earliest days of a drug’s release.
The first six weeks of a launch can make or break a drug’s future market performance. Traditional surveys and data collection practices can severely limit informed action during a critical time; shortcomings like clunky language and sluggish response times leave pharmaceutical and biopharmaceutical industry leaders lacking important insights while the clock ticks on their new medication’s honeymoon period.
Now, Amplity has completely flipped that script. The company’s new AskX platform employs first-of-its-kind AI-powered capabilities that allow leadership to create customized field surveys and explore results using advanced application of generative AI on free-text responses.
The AskX environment is entirely free-text based, meaning leaders can construct surveys and investigate their results in plain speak — without the need for extra time and personnel to make sense of survey findings. The results constitute a dramatic up-leveling in the consistency, punctuality, and value of field insights.
“Until now, there has never been a way for us to compliantly record the results of discussions between field reps and clinicians in free-text,” said Michele Graham, President of Intel and product leader for AnswerY and its’ suite of AI-powered tools. “Leaders not only had to poll their teams for anecdotal insights; they had to work to understand the results. AskX takes the answers to the client’s questions — provided in the rep’s own words — runs them through an AI-powered compliance review to flag reportable issues, and produces data that’s as easy to query and understand as a conversation over coffee.”
AskX yields the most up-to-date and easy-to-understand insights currently available to ensure launch excellence, without the data-science lift and compliance concerns that have historically existed.
Although it’s still in its earliest days, industry stakeholders are already hailing AskX as a game-changer for its speed, accuracy, and clear, concise takeaways — with the platform suggesting mid-course corrections and both microscopic and high-altitude views of the playing field.
One top pharma leader reports, “I have been offered any number of AI solutions over the past 10 years in my role as a National Sales Director. No tool has been as immediate as what I’ve seen with AskX in its ability to provide actionable feedback in real time.”
AskX is quickly taking its place alongside Amplity’s established lineup of medical and commercial solutions and other AskX capabilities. The platform also empowers users to explore patient journeys and HCP interactions through related AI-powered search channels that index millions of qualitative data points from unstructured, real-world medical transcription records. Amplity continues to evolve with cutting-edge innovations — pushing the envelope on providing actionable insights through transformational yet easy-to-navigate healthcare data.
“Survey is a natural and powerful extension of our Amplity Insights ecosystem, and further amplifies Amplity’s role as a leading global medical and commercial partner to pharmaceutical and biopharmaceutical companies,” Graham added.
About Amplity AnswerY
Amplity AnswerY is Amplity’s real-world AI-powered database and platform built from HIPAA-compliant transcriptions of U.S. prescriber–patient visits. Using AI and natural language processing (NLP), it extracts, visualizes, and summarizes treatment discussions and clinical decisions. Covering inpatient and outpatient care across 70+ specialties since 2017, AnswerY was known as Amplity Insights™ prior to January 2025.
Pharma At Its Best: Quicker. Better. Nicer.
Your full-service go-to partners delivering both flexible and specialized medical and commercial services. No matter where you are in the lifecycle of your drug, we scale with ease.
Our people-driven tech-enabled DNA fuels everything we do.
To learn more about AnswerY, please reach out to Steve Ennen, Director, New Client Partnerships, [email protected]
To connect with Amplity’s Marketing and PR team, please email [email protected].
